SABCS--2016 Dec 6-10
everyone ready?
Comments
-
-
-
My doc is presenting - and then I see him that next Monday. I'd sure like to hear some tidbits from him & I will be asking, but he's not very communicative. My wonderful MO who retired recommended this new MO since his area of interest is HER2.
-
Yeah!!
-
-
Immuno-Oncology is the hottest topic in cancer these days. Rightfully so, since Immunotherapy drugs have increased the survival rates of patients with diseases that typically have high mortality rates, including advanced forms of melanoma, bladder cancer, lung cancer, Hodgkin lymphoma, head and neck cancers, and kidney cancer.
A review of this years SABCS 2016 program reveals dozens of Abstracts focused on Immunotherapy. Most appear to be pre-clinical studies, but there's also ~100 different Phase 1 Clinical Trials exploring Immunotherapy for breast cancer. I wouldn't be surprised if we hear reports from some of these early trials about patients who have achieved a durable response.
-
-
SAN ANTONIO — Clinicians who care for postmenopausal patients with advanced, hormone receptor (HR)–positive breast cancer may now have another treatment option when resistance to endocrine-based therapy inevitably emerges.
New data show that, in this setting, the combination of everolimus (Afinitor, Novartis) and fulvestrant (Faslodex, AstraZeneca) more than doubled median progression-free survival (PFS) compared with fulvestrant alone (10.4 vs 5.1 months; hazard ratio, 0.60; P = .02).
All 130 patients in the randomized phase 2 trial were also negative for human epidermal growth factor receptor 2 (HER2) and had locally advanced or metastatic disease.
"In my opinion, this is likely to become a good treatment option for women," lead author Noah Kornblum, MD, a medical oncologist at the Albert Einstein College of Medicine in the Bronx, New York, said today at a press conference here at the 2016 San Antonio Breast Cancer Symposium (SABCS), where the study debuted.....
http://www.medscape.com/viewarticle/872974
I suggest that everyone register at the medscape website to read the entire articles there...
-
SAN ANTONIO — Despite three new trials examining the extension of adjuvant endocrine therapy in hormone-positive breast cancer, there were no easy answers here at the San Antonio Breast Cancer Symposium (SABCS) 2016. The trials were the NASPB B-42, IDEAL, and DATA studies.
"I was anticipating a new milestone of knowledge... [but] whether we like it or not, essentially these three trials did not reach statistical significance to demonstrate clear benefit for their respective aromatase inhibitor extensions," commented discussant Michael Gnant, MD, from the Medical University of Vienna, Austria.
In particular, the NASBP B-42 trial was much anticipated because it examined extending adjuvant therapy with the aromatase inhibitor (AI) letrozole (Femara, Novartis) for 5 years in patients who had initially received 5 years of adjuvant therapy with an AI (either alone or mixed sequentially with tamoxifen).
"The first extended adjuvant therapy trials (MA-17, NSABP-B33 and ABCSG-6a) investigated AIs after tamoxifen and demonstrated significant benefits for patients. However, those trials did not answer the question, should we also use extended AI treatment after AIs were used in initial adjuvant therapy? This is why NASBP B-42 is so important," said Dr Gnant....
http://www.medscape.com/viewarticle/872973
Please register at medscape to read the complete articl
-
Does 2.5 to 5 More Years of an Aromatase Inhibitor Offer Benefits? Maybe, For Some Women: 2016 San Antonio Breast Cancer Symposium, December 7, 2016
In 2012, research results showed that taking the hormonal therapy tamoxifen for 10 years instead of 5 offered more benefits for women diagnosed with early-stage, hormone-receptor-positive breast cancer, including less recurrence and better overall survival. Since that time, researchers have wondered if extending the time a woman with early-stage, hormone-receptor-positive disease took an aromatase inhibitor would offer similar benefits.
In this podcast from the 2016 San Antonio Breast Cancer Symposium, Terry Mamounas, M.D., M.P.H., medical director of the University of Florida Health Cancer Center, discusses the results of his and other studies looking at whether 2.5 to 5 additional years of Femara (chemical name: letrozole) after 5 years of an aromatase inhibitor offered better survival or lowered the number of recurrences.
Listen to the podcast to hear Dr. Mamounas talk about:
- the very specific group of women that may benefit from an additional 2.5 to 5 years of an aromatase inhibitor
- which woman should not take an additional 2.5 to 5 years of an aromatase inhibitor
- how women and their doctors can weigh the benefits and potential risks of extended aromatase inhibitor treatment
- how he plans to talk to his patients about this issue
Running time: 9:09
Listen now.
-
SAN ANTONIO, TX — Women who received postmastectomy radiation therapy (RT) experienced higher complication rates if they had implant reconstruction compared with autologous reconstruction, according to the large, prospective, multicenter Mastectomy Reconstruction Outcomes Consortium study.
"The impact of radiotherapy on breast reconstruction is widely feared but poorly understood," said investigator Reshma Jagsi, MD, DPhil, professor and deputy chair in the department of radiation oncology at the University of Michigan, who reported the results here at the 2016 San Antonio Breast Cancer Symposium.
http://www.medscape.com/viewarticle/873105
-
SAN ANTONIO ― Two agents that inhibit cyclin-dependent kinases 4 and 6 (CDK4/6) have yielded unprecedented results in progression-free survival in clinical trials involving postmenopausal women with estrogen-receptor (ER) positive, HER2-negative metastatic breast cancer.
One drug, palbociclib (Ibrance, Pfizer), is approved by the US Food and Drug Administration in this metastatic setting, and the other agent, ribociclib (Novartis), is under priority review by regulators for use in the same setting.
Now, new data on the third agent in this class, the still experimental abemaciclib (Eli Lilly), show that the strategy of inhibiting CDK4/6 has effectiveness in even more patients – those with early-stage disease.
In the first randomized neoadjuvant trial of a CDK4/6 inhibitor in early-stage patients, twice-daily abemaciclib, either alone or in combination with anastrozole (Arimidex, AstraZeneca), significantly reduced Ki67 expression after 2 weeks of presurgery treatment in comparison with anastrozole alone. Thus, the three-arm, 161-patient study met its primary endpoint.
http://www.medscape.com/viewarticle/873103
-
NEW YORK (Reuters Health) - The mutational landscape of drug-resistant estrogen receptor (ER)-positive metastatic breast cancer differs significantly from that of primary ER+ breast cancer, according to research presented today at the 2016 San Antonio Breast Cancer Symposium.
"The bottom line is that tumors do evolve and the metastatic setting is different than the primary setting," said Dr. Ofir Cohen of the Broad Institute and Dana-Farber Cancer Institute in Boston, during a press briefing.
"We were able to identify multiple clinically relevant genomic and molecular alterations in the metastatic biopsies with implications for choice of next therapy, clinical trial eligibility, and novel drug targets," he added in a conference statement.
http://www.medscape.com/viewarticle/872941
-
don't forget....register at medscape and read articles...
I like medscape because they attempt to make medical gibberish understandable....
-
I agree, VR - understandable without dumbing it down.
-
Why do some breast cancers respond to treatment while others resist it? A study led by researchers at the University of North Carolina Lineberger Comprehensive Cancer Center may provide insight into this important question.
The researchers report at the San Antonio Breast Cancer Symposium that they have identified biomarkers they believe can be used as part of a larger model to predict how patients with HER2-positive operative breast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemotherapy.
"We're trying to find biomarkers for resistance to trastuzumab treatment and chemotherapy," said the study's first author Maki Tanioka, MD, PhD, a postdoctoral research associate at UNC Lineberger. "What's the cause of response? What's the cause of resistance? That's what we are trying to identify in this genomic study."
http://www.news-medical.net/news/20161208/Scientis...
-
hope...my preference...especially with controversial studies is to go to primary sources. That said, most of us are laymen and have not taken a class in statistics to help appreciate what is being promoted. Likewise, one STILL must read carefully the data because there are inherent biases in every study...IMHO...Medscape does TRY to explain studies better than most mainstream media...
-
Voraciousreader, your post above about the faslodex + afinitor trial is very interesting to me. That has not been a standard combo, but I had already decided to propose it to my onc if/when I need to switch from Ibrance + letrozole. She has already said we would use faslodex because it is an endocrine therapy that is different from an aromatase inhibitor. I want to add something to it because I want continue to address two pathways at the same time. (The other drugs I see in trial with faslodex are for a mutation not listed in my report.)
-
VR - thanks for keeping us up to date.
-
FRIDAY, Dec. 9, 2016 -- Women on breast cancer drugs called aromatase inhibitors may show signs of early blood vessel damage that could lead to heart disease, a small study suggests.
Researchers found that compared with healthy women their age, women on aromatase inhibitors were more likely to show signs of "endothelial dysfunction." That refers to problems in how the blood vessel lining responds to blood flow.
http://www.upi.com/Health_News/2016/12/09/Breast-c...
-
A drug typically used to treat depression and anxiety can significantly reduce joint pain in postmenopausal women being treated for early stage breast cancer, according to new SWOG research to be presented Friday at a special plenary presentation at the San Antonio Breast Cancer Symposium.
Investigators from SWOG, the international cancer clinical trialsnetwork funded by the National Cancer Institute (NCI), conducted a randomized, placebo-controlled trial to test whether duloxetine, a depression and anxiety drug, could alleviate pain caused by aromatase inhibitors, a common breast cancer treatment that's particularly effective with postmenopausal women.
http://medicalxpress.com/news/2016-12-depression-d...
-
just throwing out my own personal experience...i take an AI AND a cocktail of meds that keep my pain in check. My pain predated my cancer diagnosis. My cocktail includes a depression medication despite NOT being treated for depression. The depression med, according to my physician is a cheap pain reliever. Together with an anti-inflammatory drug and a nerve blocker medication, I have GREAT quality of life. These off-label cheap meds are often helpful as long as they are prescribed by EXPERIENCED physicians. I also take daily 3 mile walks...which I am certain helps. Never felt that dietary and supplement recommendations helped much. Tried EVERYTHING!
Happy to see that these patients' joint pain was reduced by the medication!
-
VR - I, too, prefer to read the source documents and find that Medscape sometimes points me to studies I've not read. It also helps tease out relevant studies for further follow up.
-
PUBLIC RELEASE: 9-DEC-2016
EndoPredict outperforms Oncotype Dx in predicting the risk breast cancer recurrence
New data are being featured in a podium presentation at SABCS
MYRIAD GENETICS, INC.
SALT LAKE CITY, Utah, Dec. 9, 2016 - Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced results of a large head-to-head study comparing the efficacy of six tests used to predict the recurrence of breast cancer. A key finding was that EndoPredict® (EPclin), a second-generation test, was superior to Oncotype Dx™ (RS), a first-generation test, in predicting the long-term recurrence of breast cancer. The results are being featured today in a podium presentation at the 2016 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. "In this important study, EndoPredict more accurately predicted the risk of breast cancer recurrence than the first-generation Oncotype Dx test, particularly in years five to 10 following surgery when half of breast cancer recurrences will happen," said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories. "Clinicians can consider using EndoPredict to identify patients who can forgo chemotherapy with confidence, knowing they have a low risk of recurrence over 10 years."
Podium Presentation
-
TNBC clinical trial news from the conference, regarding:
Sacituzumab govitecan (IMMU-132), an anti-Trop-2 Antibody-Drug Conjugate (ADC).The science is a bit complex, but basically this therapy combines two components,
1. A cytotoxic drug, 2. A monoclonal antibody (a form of immunotherapy). They combine the two to make something called an Antibody-Drug Conjugate or ADC. The antibody targets a cell surface antigen called Trop-2, which is over-expressed in the vast majority of TNBC patients. TROP-2 has limited expression in normal human tissue, which makes it a attractive target.
The antibody hones in on the cancer cell that expresses TROP2 and when it attaches to the cell, deploys its payload (the anti-cancer drug). Cancer cell is destroyed.
http://www.onclive.com/conference-coverage/sabcs-2016/sacituzumab-govitecan-elicits-durable-responses-for-pretreated-tnbc
Excerpts from the article:
Treatment with sacituzumab govitecan (IMMU-132) was well-tolerated and induced durable responses, some lasting longer than 1 year, for heavily pretreated patients with metastatic triple-negative breast cancer (TNBC), according to findings from an ongoing phase I/II study presented at the 2016 San Antonio Breast Cancer Symposium.
In the single-arm trial, the confirmed objective response rate (ORR) was 30% with sacituzumab govitecan, and the duration of response was 8.9 months (95% CI, 6.1-11.3).
The median progression-free survival was 6.0 months (95% CI, 5.0-7.3) and the median overall survival was 16.6 months (95% CI, 11.1-20.6).
"The findings are truly outstanding," said senior study author Linda Vahdat, MD, MBA, from Weill Cornell Medical College.
"The confirmed response rate is near 30%, and what's really striking is that this is a group of patients with a median of 5 prior regimens for breast cancer—it is a very heavily pretreated population."
The ongoing study enrolled 69 patients with relapsed/refractory metastatic TNBC.
"These aren't just flash in the pan type of responses, they are actually quite durable," said Vahdat.
"When you have a drug that you can keep someone on in triple-negative breast cancer for almost a year you get excited, because the median survival in TNBC is a little under a year."
A phase III study is currently being planned under a special protocol agreement with the FDA. -
SAN ANTONIO -- Breast cancer mortality rates continue to decline in many nations, but a review of mortality trends in 47 countries around the world indicates some significant disparities, particularly in South Korea and some Latin American nations, according to results presented at the 2016 San Antonio Breast Cancer Symposium, held Dec. 6-10.
"Breast cancer is by far the primary cancer site in women and, worldwide, represents a quarter of all cancers in women," said the study's lead author, Cécile Pizot, MSc, at the International Prevention Research Institute in Lyon, France. "Comparing mortality trends between countries helps identify which health care systems have been the most efficient at reducing breast cancer mortality."
In this study, Pizot and colleagues extracted information on breast cancer deaths from the World Health Organization database and calculated mortality rates over the years 1987-2013, stratifying results according to age groups.
Overall, breast cancer mortality declined in 39 out of 47 countries, including the United States and most developed European nations. England and Wales had the sharpest drop in mortality, with a 46 percent decline. Pizot said this trend was to be expected, due to advances in detection and treatment over the past few decades....
-
the above referenced article is quite interesting...and sobering...once again...IMHO...there is accummulating evidence that as mortality improves..claiming that mammography is the chief component, is simply not true. we need to do better at finding a more effective way of screening..
-
Patient health records revealed two drug combinations that may reduce mortality rates in breast cancer patients, according to a study led by researchers at the Stanford University School of Medicine.
The drugs involved were commonly used drugs that turned out to be associated with a longer average survival rate in breast cancer patients.
The study will be published online Dec. 9 in the Journal of the American Medical Informatics Association. The lead author is Stanford postdoctoral scholar Yen Low, PhD. The senior author is Nigam Shah, MBBS, PhD, associate professor of medicine and of biomedical data science.
Often, when different drugs are taken together, they can have unexpected side effects. For example, some antibiotics and antifungal drugs can interfere with the effectiveness of birth control pills. It occurred to Shah and his team that the opposite could also be true -- that some drug interactions might help patients....
http://www.news-medical.net/news/20161209/Two-drug...
-
voraciousreader...
Was the above Stanford research part of SABCS? Either way, it's interesting. I don't think it comes to any surprise that there are numerous existing FDA approved drugs that are not indicated for any type cancer, but may have benefit, especially when used in combination. The notion of "re-purposing" them for cancer is a rational thought. These drugs have been around for decades and have a proven safety profile. If these combo's were pursued in clinical trials, I wonder if Phase 1 trials could be eliminated, thus accelerating the trial process.
-
Circulating tumor DNA (ctDNA) measured by liquid biopsy was able to identify actionable mutations and provide a real-time molecular assessment of metastatic breast cancer. The most common mutations found included TP53 (52%), PIK3CA (40%), ERBB2 (20%), NOTCH1 (15.5%), APC (14%), and MET (13%).
http://www.cancernetwork.com/SABCS-2016/liquid-biopsy-finds-actionable-mutations-metastatic-breast-cancer
Categories
- All Categories
- 679 Advocacy and Fund-Raising
- 289 Advocacy
- 68 I've Donated to Breastcancer.org in honor of....
- Test
- 322 Walks, Runs and Fundraising Events for Breastcancer.org
- 5.6K Community Connections
- 282 Middle Age 40-60(ish) Years Old With Breast Cancer
- 53 Australians and New Zealanders Affected by Breast Cancer
- 208 Black Women or Men With Breast Cancer
- 684 Canadians Affected by Breast Cancer
- 1.5K Caring for Someone with Breast cancer
- 455 Caring for Someone with Stage IV or Mets
- 260 High Risk of Recurrence or Second Breast Cancer
- 22 International, Non-English Speakers With Breast Cancer
- 16 Latinas/Hispanics With Breast Cancer
- 189 LGBTQA+ With Breast Cancer
- 152 May Their Memory Live On
- 85 Member Matchup & Virtual Support Meetups
- 375 Members by Location
- 291 Older Than 60 Years Old With Breast Cancer
- 177 Singles With Breast Cancer
- 869 Young With Breast Cancer
- 50.4K Connecting With Others Who Have a Similar Diagnosis
- 204 Breast Cancer with Another Diagnosis or Comorbidity
- 4K DCIS (Ductal Carcinoma In Situ)
- 79 DCIS plus HER2-positive Microinvasion
- 529 Genetic Testing
- 2.2K HER2+ (Positive) Breast Cancer
- 1.5K IBC (Inflammatory Breast Cancer)
- 3.4K IDC (Invasive Ductal Carcinoma)
- 1.5K ILC (Invasive Lobular Carcinoma)
- 999 Just Diagnosed With a Recurrence or Metastasis
- 652 LCIS (Lobular Carcinoma In Situ)
- 193 Less Common Types of Breast Cancer
- 252 Male Breast Cancer
- 86 Mixed Type Breast Cancer
- 3.1K Not Diagnosed With a Recurrence or Metastases but Concerned
- 189 Palliative Therapy/Hospice Care
- 488 Second or Third Breast Cancer
- 1.2K Stage I Breast Cancer
- 313 Stage II Breast Cancer
- 3.8K Stage III Breast Cancer
- 2.5K Triple-Negative Breast Cancer
- 13.1K Day-to-Day Matters
- 132 All things COVID-19 or coronavirus
- 87 BCO Free-Cycle: Give or Trade Items Related to Breast Cancer
- 5.9K Clinical Trials, Research News, Podcasts, and Study Results
- 86 Coping with Holidays, Special Days and Anniversaries
- 828 Employment, Insurance, and Other Financial Issues
- 101 Family and Family Planning Matters
- Family Issues for Those Who Have Breast Cancer
- 26 Furry friends
- 1.8K Humor and Games
- 1.6K Mental Health: Because Cancer Doesn't Just Affect Your Breasts
- 706 Recipe Swap for Healthy Living
- 704 Recommend Your Resources
- 171 Sex & Relationship Matters
- 9 The Political Corner
- 874 Working on Your Fitness
- 4.5K Moving On & Finding Inspiration After Breast Cancer
- 394 Bonded by Breast Cancer
- 3.1K Life After Breast Cancer
- 806 Prayers and Spiritual Support
- 285 Who or What Inspires You?
- 28.7K Not Diagnosed But Concerned
- 1K Benign Breast Conditions
- 2.3K High Risk for Breast Cancer
- 18K Not Diagnosed But Worried
- 7.4K Waiting for Test Results
- 603 Site News and Announcements
- 560 Comments, Suggestions, Feature Requests
- 39 Mod Announcements, Breastcancer.org News, Blog Entries, Podcasts
- 4 Survey, Interview and Participant Requests: Need your Help!
- 61.9K Tests, Treatments & Side Effects
- 586 Alternative Medicine
- 255 Bone Health and Bone Loss
- 11.4K Breast Reconstruction
- 7.9K Chemotherapy - Before, During, and After
- 2.7K Complementary and Holistic Medicine and Treatment
- 775 Diagnosed and Waiting for Test Results
- 7.8K Hormonal Therapy - Before, During, and After
- 50 Immunotherapy - Before, During, and After
- 7.4K Just Diagnosed
- 1.4K Living Without Reconstruction After a Mastectomy
- 5.2K Lymphedema
- 3.6K Managing Side Effects of Breast Cancer and Its Treatment
- 591 Pain
- 3.9K Radiation Therapy - Before, During, and After
- 8.4K Surgery - Before, During, and After
- 109 Welcome to Breastcancer.org
- 98 Acknowledging and honoring our Community
- 11 Info & Resources for New Patients & Members From the Team